(1) Saint Louis University School of Medicine, Saint Louis, Missouri, USA
* Corresponding author Email:
G protein coupled receptors (GPCRs) represent the most abundant receptor family encoded by the human genome, and are the targets of a large percentage of drugs currently prescribed in the United States. Recently, several GPCRs have been identified as potential therapeutic targets for the treatment of diabetes and diabetes-associated complications, including retinopathy, nephropathy, and neuropathy.
In this review, we will discuss GPCR structure and signalling cascades, as well as highlight GPCR-based therapeutics that are currently prescribed or are in clinical trials to combat diabetes and its complications, a disease which now affects over 347 million patients worldwide.